Cabergoline treatment promotes myocardial recovery in peripartum cardiomyopathy. (27th October 2022)

• Record Type: Journal Article
• Authors: Pfeffer, Tobias J.; Mueller, Julia H.; Haebel, Lea; Erschow, Sergej; Yalman, Kuebra C.; Talbot, Steven R.; Koenig, Tobias; Berliner, Dominik; Zwadlo, Carolin; Scherr, Michaela; Hilfiker‐Kleiner, Denise; Bauersachs, Johann; Ricke‐Hoch, Melanie
• Is Part Of: ESC heart failure. Volume 10:Number 1(2023)
• Page Start: 465
• Page End: 477
• Publication Date: 2022-10-27
• Subjects: Peripartum cardiomyopathy (PPCM) -- Dopamine D2 receptor agonist -- Bromocriptine -- Cabergoline -- Heart failure; Heart failure -- Periodicals; 616.129005
• DOI: 10.1002/ehf2.14210
• Languages: English
• ISSNs: 2055-5822

Abstract

Abstract: Aims: Peripartum cardiomyopathy (PPCM) is a rare heart disease, occurring in previously heart‐healthy women during the last month of pregnancy or the first months after delivery due to left ventricular (LV) systolic dysfunction. A common pathomechanistic pathway of PPCM includes increased oxidative stress and the subsequent generation of a cleaved prolactin fragment (16 kDa PRL), which promotes the onset of heart failure (HF) in a microRNA (miR)‐146a‐dependent manner. Inhibition of prolactin secretion with the dopamine D2 receptor (D2R) agonist bromocriptine combined with standard HF therapy supports cardiac recovery. This study examined whether treatment with the more selective D2R agonist cabergoline prevents HF development in an experimental PPCM mouse model and might be used as an alternative treatment regime for PPCM. Methods and results: Postpartum (PP) female PPCM‐prone mice with a cardiomyocyte restricted STAT3‐deficiency (αMHC‐Cre tg/+ ; Stat3 fl/fl ; CKO) were treated over two consecutive nursing periods with cabergoline (CKO Cab, 0.5 mg/kg/day) and were compared with bromocriptine treated CKO (CKO Br) and postpartum‐matched WT and CKO mice. Cabergoline treatment in CKO PP mice preserved cardiac function [fractional shortening (FS): CKO Cab: 34.5 ± 9.4% vs. CKO: 22.1 ± 9%, P < 0.05] and prevented the development of cardiac hypertrophy, fibrosis, and inflammation as effective as bromocriptine therapy (FS: CKO Br: 33.4 ± 5.6%). The myocardial up‐regulation of the PPCM biomarkers plasminogen inhibitor activator 1 (PAI‐1) and miR‐146a were prevented by both cabergoline and bromocriptine therapy. A small cohort of three PPCM patients from the German PPCM Registry was treated with cabergoline (1 mg per week for 2 weeks, followed by 0.5 mg per week for another 6 weeks) due to a temporary unavailability of bromocriptine. All PPCM patients initially presented with a severely reduced LV ejection fraction (LVEF: 26 ± 2%). However, at 6 months of follow‐up, LV function (LVEF: 56 ± 2%) fully recovered in all three PPCM patients, and no adverse events were detected. Conclusions: In the experimental PPCM mouse model, the selective D2R agonist cabergoline prevents the onset of postpartum HF similar to bromocriptine. In PPCM patients, cabergoline treatment was safe and effective as all patients fully recovered. Cabergoline might serve as a promising alternative to bromocriptine. However, these findings are based on experimental data and a small case series and thus have to be interpreted with caution and should be validated in a larger clinical trial.